The blast counts
in the specimens tested ranged from 5% to 71% with a mean value of 25% in peripheral blood.
Identification of the cytogenetic fusion transcripts is considered diagnostic of acute leukemia, even when the blast count
is less than 20%.
An increased blast count
is suggested by an increased percentage of CD34-positive cells.
If there are more than 50% erythroid precursors, the erythroid progenitors are also excluded from the blast count
The notable peripheral blood monocytosis (2,000/ml) and bone marrow blast count
of 10% were indicative of CMML, and flow cytometry immunophenotypic analysis and special staining were confirmatory.
If the blast count
is less than 20% of all nucleated cells and also less than 20% of the nonerythroid elements, a diagnosis of MDS is most appropriate.
Results of Bone Marrow Studies Initial Admission 3 Weeks Later With Varicella With ALL Cellularity Decreased 100% increased Morphology Decreased in all cell lines Total replacement by ALL-L, blasts Blast count
0% 82% Megakaryocytes Decreased Absent ALL = Acute lumphocytic leukemia.
2 biphenotypic Poor (71 ALL, high blast count
449 adults 2 CD117 N.
of more than 5% was proven to be a poor prognostic factor .
The assay helped resolve complex cytogenetic cases, positively identified the expected fusion transcript in RNA samples from cases with low blast count
, and resulted in 99% agreement (196/198)* with standard cytogenetic methods.
In phase I and II clinical trials in patients who have a limited number of approved treatments for their diseases, rigosertib has demonstrated significant bone marrow blast count
improvement (at least 50% blast reduction) in 53% of MDS patients and greater than 50% reduction in CA 19-9 marker in about 36% of patients with pancreatic cancer.
Na resulted in significant decrease in blast count
(cancer cells) in bone marrow without significant toxicity in these high risk MDS patients.
Among four MDS patients with aggressive disease that had progressed following azacitidine or decitabine treatment, one achieved complete remission and two achieved a decrease in bone marrow blast count
to 5% or less.